960 related articles for article (PubMed ID: 26451606)
21. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
22. Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways.
Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Shankar S; Srivastava RK
PLoS One; 2014; 9(4):e92161. PubMed ID: 24694877
[TBL] [Abstract][Full Text] [Related]
23. Anthothecol-encapsulated PLGA nanoparticles inhibit pancreatic cancer stem cell growth by modulating sonic hedgehog pathway.
Verma RK; Yu W; Singh SP; Shankar S; Srivastava RK
Nanomedicine; 2015 Nov; 11(8):2061-70. PubMed ID: 26199979
[TBL] [Abstract][Full Text] [Related]
24. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells.
Suman S; Kurisetty V; Das TP; Vadodkar A; Ramos G; Lakshmanaswamy R; Damodaran C
Mol Carcinog; 2014 Feb; 53 Suppl 1():E151-60. PubMed ID: 24000138
[TBL] [Abstract][Full Text] [Related]
25. Sonic hedgehog inhibitors prevent colitis-associated cancer via orchestrated mechanisms of IL-6/gp130 inhibition, 15-PGDH induction, Bcl-2 abrogation, and tumorsphere inhibition.
Kangwan N; Kim YJ; Han YM; Jeong M; Park JM; Go EJ; Hahm KB
Oncotarget; 2016 Feb; 7(7):7667-82. PubMed ID: 26716648
[TBL] [Abstract][Full Text] [Related]
26. Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.
Yin T; Wang G; He S; Shen G; Su C; Zhang Y; Wei X; Ye T; Li L; Yang S; Li D; Guo F; Mo Z; Wan Y; Ai P; Zhou X; Liu Y; Wang Y; Wei Y
J Biol Chem; 2016 Dec; 291(52):26750-26761. PubMed ID: 27756837
[TBL] [Abstract][Full Text] [Related]
27. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.
Sharon C; Baranwal S; Patel NJ; Rodriguez-Agudo D; Pandak WM; Majumdar AP; Krystal G; Patel BB
Oncotarget; 2015 Jun; 6(17):15332-47. PubMed ID: 25895029
[TBL] [Abstract][Full Text] [Related]
29. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Zhou H; Yu C; Kong L; Xu X; Yan J; Li Y; An T; Gong L; Gong Y; Zhu H; Zhang H; Yang X; Li Y
Oncogene; 2019 May; 38(18):3371-3386. PubMed ID: 30635656
[TBL] [Abstract][Full Text] [Related]
30. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.
Miyazaki Y; Matsubara S; Ding Q; Tsukasa K; Yoshimitsu M; Kosai K; Takao S
Mol Cancer; 2016 Jun; 15(1):49. PubMed ID: 27349387
[TBL] [Abstract][Full Text] [Related]
31. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
[TBL] [Abstract][Full Text] [Related]
32. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
34. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
[TBL] [Abstract][Full Text] [Related]
35. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
[TBL] [Abstract][Full Text] [Related]
36. Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice.
Zhao M; Tang SN; Marsh JL; Shankar S; Srivastava RK
Cancer Lett; 2013 Sep; 337(2):210-7. PubMed ID: 23684930
[TBL] [Abstract][Full Text] [Related]
37. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway.
Chang L; Wu P; Senthilkumar R; Tian X; Liu H; Shen X; Tao Z; Huang P
J Cancer Res Clin Oncol; 2016 Jan; 142(1):59-72. PubMed ID: 26109148
[TBL] [Abstract][Full Text] [Related]
38. Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells.
Kim MH; Jeong YJ; Cho HJ; Hoe HS; Park KK; Park YY; Choi YH; Kim CH; Chang HW; Park YJ; Chung IK; Chang YC
Oncol Rep; 2017 Feb; 37(2):777-784. PubMed ID: 27959445
[TBL] [Abstract][Full Text] [Related]
39. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway.
Tu M; Wange W; Cai L; Zhu P; Gao Z; Zheng W
Tumour Biol; 2016 Nov; 37(11):14701-14709. PubMed ID: 27623944
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
